PRTA News and Press, Prothena Corporation plc From 01/30/24

2024-01-30 11:05:09 ET More on Prothena Prothena: Upcoming Alzheimer's Data Could Solidify Its Position In The Market Prothena stock tumbles 23% in premarket trading Seeking Alpha’s Quant Rating on Prothena Historical earnings data for Prothena ...

2024-01-09 15:45:01 ET JMP Securities analyst issues MARKET OUTPERFORM recommendation for PRTA on January 9, 2024 04:00PM ET. The previous analyst recommendation was Market Outperform. PRTA was trading at $39.62 at issue of the analyst recommendation. The overall analyst...

2024-01-08 12:31:25 ET Gainers: Harpoon Therapeutics ( HARP ) +112% . Ambrx Biopharma ( AMAM ) +101% . Nkarta ( NKTX ) +47% . Mountain Crest Acquisition Corp IV ( MCAF ) +45% . Spectaire Holdings ( SPEC ) +43% . Neximmune ( ...

2024-01-08 10:00:05 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Covid-vaccine makers top laggard list, LLY and WST top gainers list Healthcare and uti...

2024-01-08 09:29:35 ET More on Prothena Prothena: Upcoming Alzheimer's Data Could Solidify Its Position In The Market Prothena, BioVie among decliners after Biogen data for new Alzheimer’s therapy Prothena jumps on report company may explore a potential sale ...

Updates on PRX012 and PRX123 for treatment of Alzheimer’s disease, and on birtamimab for treatment of AL amyloidosis Remain on track with partnered programs: Bristol Myers Squibb (BMS-986446 for the treatment of Alzheimer’s disease), Roche (Prasinezumab for the treatment of Park...

2024-01-03 07:00:00 ET Summary The biotech industry experienced a challenging year in 2023 due to a rising 10-year Treasury yield. In 2024, the 10-year yield should favorably support biotech stocks. Promising advancements in weight loss drugs, neuroscience, oncology, and gene ...

2023-12-23 00:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-12 05:00:00 ET Summary Prothena’s PRX012, targeting Alzheimer's, shows promise in Phase 1, potentially advancing Alzheimer’s treatment with subcutaneous administration. Strong Q3 earnings with revenue surge to $84.9M; however, increased operating expenses hig...

2023-11-02 16:14:22 ET More on Prothena Prothena: Switching From 'Hold' To 'Buy' On Lead Alzheimer's Drug Promise Prothena (PRTA) Investor Presentation - Slideshow Prothena, BioVie among decliners after Biogen data for new Alzheimer’s therapy Prothena ...